In the past, investigators have used thyroxine labeled either with JIP" in the 3',5'-position or with C14 in the carboxyl position to study the metabolism of thyroxine in vivo. Although these studies have yielded much valuable information, our knowledge about the metabolic fate of the ring structure in thyroxine is incomplete because both the 3'5'-IJ13 and the carboxyl-C14 are rapidly removed from thyroxine in vivo by deiodination and .decarboxylation. To investigate the metabolic fate of the thyroxine nucleus, L-thyroxine-C14 labeled uniformly in the phenolic ring has been synthesized in our laboratory. Studies on the metabolism of ring-labeled L-thyroxine-C14 following iv administration to rats, dogs, and human subjects are reported in this communication.
In the past, investigators have used thyroxine labeled either with JIP" in the 3',5'-position or with C14 in the carboxyl position to study the metabolism of thyroxine in vivo. Although these studies have yielded much valuable information, our knowledge about the metabolic fate of the ring structure in thyroxine is incomplete because both the 3'5'-IJ13 and the carboxyl-C14 are rapidly removed from thyroxine in vivo by deiodination and .decarboxylation. To investigate the metabolic fate of the thyroxine nucleus, L-thyroxine-C14 labeled uniformly in the phenolic ring has been synthesized in our laboratory. Studies on the metabolism of ring-labeled L-thyroxine-C14 following iv administration to rats, dogs, and human subjects are reported in this communication.
METHODS AND MATERIALS
Synthesis of ring-labeled L-thyroxine-C"4.1 The L-thyroxine-C1' labeled in the phenolic ring was prepared from uniformly labeled phenol-C14 in 2.6% over-all yield in the following manner: phenol-C1' was converted to 4-methoxyphenol-C1' by a series of reactions that included the formation of phenylbenzene sulfonate, nitration to the 4-nitro ester, saponification to 4-nitrophenol, methylation to the ether, reduction of the nitro group to 4-methoxyaniline, diazotization of the amino group, and finally hydrolysis of the diazonium salt. The conversion of 4-methoxyphenol-C1' to L-thyroxine-C1' was accomplished by modification of a route developed by Chalmers, Dickson, Elks, and Hems (1) via 3,5-dinitro-N-acetyl-L-tyrosine ethyl ester.2
The L-thyroxine-C1' possessed the following physical constants: melting range 233 to 234°(with decomposition), [a] D' -5.6, SA 1.55 ,uc per mg. It was compared with nonradioactive and P`3-labeled L-thyroxine by decending paper chromatography in three different solvent systems: 2-methyl-2-butanol saturated with 2 N ammonium hydroxide (TAA), n-butanol: p-dioxane: 2 N am-1 Throughout this manuscript L-thyroxine-C1' refers to L-3-[4-(4-hydroxy-3,5-diiodophenoxy-1,2,3,4,5,6-C1) -3,5- diiodophenyl]alanine, unless otherwise specified. 2 Manuscript describing experimental details is in preparation and will be published elsewhere. L-Thyroxine (3',5'-PJ1f). The L-thyroxine-13 used in these experiments was labeled in the 3',5'-positions and was obtained commercially.3 It was demonstrated to be radioactively homogeneous by paper chromatography before use. Experimental subjects. The metabolism of L-thyroxine-C14 was investigated in three intact dogs, three intact rats, and nine rats with their common bile ducts cannulated. With the information obtained from these animal experiments, permission was obtained from the Atomic Energy Commission to study the metabolism of L-thyroxine-C1' in two patients with inoperable carcinoma.
For the balance experiments, in which an attempt was made to account for all of the administered radioactivity, rats were kept in gas-tight, all-glass metabolic cages for the separate collection of urine, feces, and expired CO2. The amount of radioactivity in the expired CO2 was measured quantitatively by a modification of the method of Fredrickson and Ono (5). Comparable balance experiments could not be carried out in man and dog because the specific activity of the L-thyroxine-C1' was not high enough to permit accurate measurement of radioactivity in the large quantity of feces and CO2 produced by these species.
The dogs were kept in metabolic cages to allow for the collection of urine and feces separately. The human subjects were housed on the metabolic ward for the entire experimental period.
Between 3 Asg (.0046 ptc) and 116 lg (0.180 4Ac) of ringlabeled L-thyroxine-C' dissolved in 0.2 ml of rat serum was administered via the tail vein to rats. With the human subjects and dogs, L-thyroxine-C1' was administered intravenously in doses of 0.4 to 0.5 mg (0.62 to 0.78 sAc) dissolved in 5 ml of the experimental subjects' own serum.
A sample of the inj ected serum was set aside for accurate counting of radioactivity and for paper chromatography. In all experiments, thyroxine was the only radioactive substance in the injected serum, as determined by paper chromatographic analysis.
sAbbott Laboratories, North Chicago, Ill, Urine samples were collected at the specified time intervals. Feces were collected in 3-day pools.
Measurement of radioactivity. C14 in urine and plasma was measured quantitatively by liquid scintillation counting, as described by Chen (6) . Fecal samples were homogenized, and samples were plated and counted with a Nuclear-Chicago counter, model C-115, with an automatic sample changer and a guard tube for low background counting. I" in samples of urine, feces, plasma, and bile was measured in a well counter by conventional solid scintillation gamma counting techniques.
Paper chromatography. Samples of plasma, bile, and urine were applied directly to Whatman no. 3 filter paper strips and developed routinely in n-butanol: p-dioxane: 2 N ammonium hydroxide (4:1:5 vol/vol) (BDA) and n-butanol: acetic acid: water (4: 1: 5 vol/vol) (BAA). In some instances, 2-methyl-2-butanol saturated with 2 N ammonium hydroxide (TAA) was also used. Radioactive tracings of paper chromatograms were made by a thin-window gas-flow Geiger-Muller detector with a mechanical scanner coordinated to a suitable recorder.
In the double-isotope experiments, I3"-labeled metabolites were distinguished from C14-labeled metabolites by scanning the paper chromatograms before and after the I.3. had decayed. For quantitation, samples with both radioactive labels were counted first for 13. with gamma counting techniques, and then for C14 after the I' had decayed.
RESULTS
Balance studies. Balance studies, in which an attempt was made to account for all of the administered radioactivity, were carried out only with rats, by use of gas-tight, all-glass metabolic cages. As shown in Table I , nearly all of the administered radioactivity could be accounted for by 13 days after administration. The major excretory route was via the feces; urinary excretion accounted for a smaller but significant proportion of the administered radioactivity. In two rats, the respiratory CO2 was collected continuously for 9 hours after the administration of L-thyroxine-C"4. A significant amount of radioactivity 4 Nuclear-Chicago Corp., Des Plaines, Ill. (0.1% of the dose) could be detected in the expired CO2 only during the first hour.
Urinary excretion of radioactivity. The cumulative excretion of radioactivity in urine for rat, man, and dog is shown in Figure 1 . On the basis of percentage of administered dose of radioactivity, man and rat ultimately excreted essentially the same amount in the urine (approximately 30%o of dose), whereas the dog excreted much less (approximately 7% of the dose). The rate of excretion of radioactivity in the urine was greatest in the rat for the first 4 days, with the excretion tending to level off thereafter, but still continuing at a detectable level for 13 days. In the dog, most of the radioactivity was excreted during the first 24 hours, but detectable amounts of radioactivity were excreted in the urine for 14 days. The rate of urinary excretion was least rapid in man during the first 24 hours, but more sustained thereafter than in the other two species.
Biliary excretion of radioactivity. When ringlabeled L-thyroxine-C14 was administered to rats with their common bile ducts cannulated, radioactivity was excreted into the bile, as shown in Figure 2 . The cumulative excretion curve reveals a fast component from 0 to 10 hours following injection, after which excretion occurred at a slower constant rate up to 56 hours. That the excretion of radioactivity in the bile was exponential from 10 to 56 hours after administration is %OF ADM. suggested by the semilogarithmic plot of the residual C14 ultimately excreted in the bile against time, which was linear ( Figure 2 ). The halftime for this phase of biliary excretion was 10.1 hours.
With complete collection of all bile formed during the experiment, the amount of radioactivity excreted in the urine was approximately 10% of the administered radioactivity, or about i the amount excreted by intact rats. This marked reduction in urinary radioactivity in rats with biliary fistulas suggests that much of the urinary radioactivity excreted by intact animals must arise from material which is initially excreted in the bile and which re-enters the general circulation, presumably through an enterohepatic cycle. An enterohepatic cycle in thyroxine metabolism has been reported previously (7) .
Characterization of metabolites of ring-labeled L-thyroxine-C14
Urinary metabolites of ring-labeled L-thyroxine-C'4. In an attempt to identify the radioactive material in the urine of rats given L-thyroxine-CY4, small samples (up to 300 jul) of urine were applied directly to paper chromatograms, which were developed in BDA. A single radioactive peak was observed with a mobility corresponding to thyroxine glucuronide (Figure 3 ). When this material was chromatographed in BAA, however, its mobility differed markedly from that expected for thyroxine glucuronide. Further evidence that this unknown metabolite was not thyroxine glucuronide was supplied by the demonstration that no thyroxine was released upon incubation with bacterial 8-glucuronidase.5 The behavior of this metabolite upon chromatography in three different solvent systems (BDA, TAA, and BAA) was dissimilar from that of any known free iodinated tyrosines or thyronines.
The possibility that this unknown metabolite might be thyroxine sulfate was considered, and hydrolysis was attempted with sulfatase 6 and acid hydrolysis (pH 1, 15 hours at room temperature). Only the original unknown material was found following these hydrolyses, suggesting that the unknown urinary metabolite was not thyroxine sulfate.
The unknown urinary metabolite proved to be much more soluble in water than thyroxine, as shown by the observation that the usual methods of extracting thyroxine from aqueous solutions with butanol were unsuccessful in extracting the unknown metabolite from urine. When lyophi- lized urine was extracted continuously in a So) extractor for 24 hours successively with he) ether, ethyl acetate, ethanol, butanol, and w the final water extract contained most of the rn activity. So far, it has not been possible to < rate this unknown metabolite from the inorg salts in urine, or to extract the material in suffi concentration for further characterization.
The radioactivity in the urine of dogs and could not be concentrated sufficiently for id fication of metabolites by paper chromatogrz The radioactivity in the urine of these two sp( however, was similar in solubility to that rats.
Biliary metabolites of ring-labeled L-thyro C'4. When bile from rats was applied direct paper and developed in BDA, three distinct separate peaks of radioactivity were observe shown in Figure 4 . The least polar peak c sponded in mobility to thyroxine. This ideni tion was confirmed by chromatography in and TAA. The radioactive peak with interi ate polarity corresponded to thyroxine g ronide. This identification was confirmed chromatography in other solvent systems and by the fact that the material was converted quantitatively to free thyroxine when incubated with /3-glucuronidase. The relative proportion of these metabolites in the bile depended upon the time of sampling after injection. Free thyroxine was the major component up to 6 hours after inection, after which thyroxine glucuronide became predominant. Free thyroxine usually could not be detected in bile by 9 hours after injection and thereafter.
The third radioactive material in Figure 4 , which barely moved off the origin, accounted for a maximum of 20%o of the total radioactivity in the bile. Its identity has not been established.
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day).
In all of the double-isotope experiments, the excretion of Il3l in the urine exceeded the excretion of C14. This observation was most striking in the dog, where the excretion of I"' in the urine exceeded the excretion of C14 by a factor of 4 to 5. In man, the excretion of Il1l in the urine exceeded the excretion of C14 by a factor of 2 to 3 for the first 3 days after injection. Thereafter, the rates of C14 and I13l excretion in the urine were essentially the same. In intact rats, the excretion of 1131 in the urine exceeded the excretion of C14 by about 30%. In rats with their bile ducts cannulated, the excretion of C14 into the bile exceeded the excretion of I131 by about 10%'.
C14-labeled metabolites could not be obtained in sufficient concentration from the urine of dog or man for detection by paper chromatography because of the problems discussed above. However, I131-labeled metabolites were detectable after samples of urine were chromatographed directly on paper. In man, the only I131-labeled metabolite observed in urine was iodide, but in the dog, approximately 20% of the total urinary I131 was accounted for in thyroxine glucuronide, and another 10 to 15% was found in an unidentified metabolite which was slightly more polar than thyroxine glucuronide. The remaining I131 (70 to 75%o) was excreted in the urine as iodide.
When the urine from a rat receiving a mixture of 1131-and C"4-labeled thyroxine was analyzed by paper chromatography, the radioactive tracing shown in Figure 6 was obtained. Before the decay of I13l, two radioactive peaks were observed. One of these peaks was radioactive iodide, and the other was the material that had been observed before in rats after the administration of L-thyroxine-C14 alone. After all the I131 had decayed, the paper chromatogram was scanned again for radioactivity. The peak of radioactive iodide had now disappeared, but the other peak still remained ( Figure 6 ). Since the size of the radioactive peak of this unknown metabolite was essentially the same after the decay of J131 as it was before, it was concluded that it contained only C14 and no J131, indicating loss of iodine from the 3',5'-positions. DISCUSSION In addition to confirming many of the results obtained in the past with thyroxine labeled in other positions, this study with ring-labeled L-thyroxine-C14 has yielded new information on the over-all metabolism of thyroxine and has reopened the question of the importance of the urinary route of excretion. Seven to 30%o of the administered radioactivity in ring-labeled L-thyroxine-C14 was excreted in the urine by three animal species.
Most, if not all, of the C14 in rat urine could be accounted for in a single compound that had lost iodine from the 3',5'-positions, as indicated by the double-isotope experiments. In the past, studies with I131-thyroxine labeled in the 3',5'-posi-tions, or with C14-carboxyl-labeled thyroxine have not indicated the existence of this unknown urinary metabolite, presumably because of loss of the radioactivity by deiodination or decarboxylation, which are known to occur rapidly in vivo (8, 9) .
The identity of the urinary metabolite arising from ring-labeled L-thyroxine-C14 in rats has not been established in this study, but some of its properties have been determined that permit us to exclude certain known thyroxine metabolites from consideration and to speculate on the probable chemical structure of this compound. After the administration of I131-labeled thyroxine, it has been reported that free thyroxine (10), thyroxine glucuronide (10), and tetraiodothyropyruvic acid (11 ) are excreted in the urine by rats. ' We failed to demonstrate any of these compounds in rat urine after the administration of ring-labeled L-thyroxine-C14. This failure might have been due to the low energy of the C14 isotope and the low concentration of these compounds in urine. Certainly the major unidentified C14-labeled metabolite in rat urine was none of these, judged not only by the evidence for loss of iodine from the phenolic ring, but also by the totally different behavior on paper chromatography.
The negligible amount of C14 in the respiratory CO2 of the rat after the administration of ringlabeled L-thyroxine-C14 suggests that the phenolic ring in thyroxine is not broken down in vivo. If this is true, the unknown urinary metabolite would probably be either a phenol or a diphenyl ether, depending upon whether the ether bond is broken. With the phenolic ring of thyroxine labeled, it is impossible to differentiate between these two possibilities.
The solubility of this unknown urinary metabolite in water suggested that it might be a saltforming acid conjugate. However, the failure to obtain any evidence for hydrolysis with glucuronidase,7 sulfatase,7 and acid argued against conjugation with glucuronic or sulfuric acids. It should be emphasized, however, that conjugation with some other acid, or even with glucuronic or sulfuric acids, cannot be absolutely ruled out on the basis of evidence of this type where the chemical nature of the substrate, its enzymatic specificity, and its reaction to acid hydrolysis are entirely unknown.
The possibility that the urinary radioactivity represented urea was considered, in spite of the lack of C1402 in the expired air, and ruled out on the basis of chromatographic behavior and the observation that incubation with urease had no effect upon the level of the radioactivity in the urine.
Whether man and dog also excrete this unknown thyroxine metabolite in the urine could not be adequately examined because of the failure to extract and concentrate the material from the large urine volumes excreted by these species. However, both man and dog excreted considerable amounts of C14-labeled material in the urine, with solubility properties similar to those observed in the rat.
Our results on biliary excretion are in agreement with the reports of others that thyroxine glucuronide is the major metabolite of thyroxine excreted in bile (7, (12) (13) (14) . Free thyroxine was demonstrable in bile only for a few hours after injection. No evidence was obtained for the conversion of ring-labeled L-thyroxine-C14 to tetraiodothyroacetic or tetraiodothyropyruvic acids, both of which have been reported in bile after the administration of I131-labeled thyroxine (14) (15) . Because of the low energy of the C14 isotope and the low concentration of these compounds usually found in bile, however, it is possible that they might have been present but not detected.
A third C14-labeled biliary metabolite, which was highly polar and comprised as much as 20%o of the total radioactivity in bile, has not been identified. The possibility that it might be thyroxine sulfate, which has been reported in bile (16) , was considered unlikely, since the material was not altered by acid or enzymatic hydrolysis.
Most of the administered radioactivity in L-thyroxine-C14 was excreted in feces in the form of free thyroxine, an observation which has been previously reported with the use of I131-labeled thyroxine (7). Abnormally high concentrations would also affect the rate of excretion. The apparent biphasic curves for the excretion of radioactivity into both bile and urine and for the decay of plasma radioactivity could be due to a change in plasma concentration of thyroxine and its metabolites.
Although the results from this study might not apply to the normal physiological disposal of thyroxine, this investigation has yielded valuable information on potential routes of metabolism. The identification of metabolites of thyroxine in excreta, even under unphysiological conditions, means that the body has the necessary enzyme systems to carry out the observed metabolic conversions. To what extent these metabolic pathways are utilized under normal physiological conditions can only be determined when ring-labeled thyroxine with much higher specific activity becomes available, so that tracer doses can be administered without disturbing the normal levels in the body's metabolic pools.
SUMMARY
To investigate the metabolic fate of the ring structure of thyroxine, L-thyroxine-C14 with the phenolic ring uniformly labeled was administered intravenously to rat, dog, and man with the following results:
1. Approximately 67% of the administered C14 was excreted in the feces by rats, with free thyroxine accounting for about 90% of the total fecal radioactivity.
2. Rat, dog, and man all excreted appreciable amounts of radioactivity in urine, with the dog excreting 7%; man, 25%o; and the rat, 30% of the administered C'4 within 2 weeks of injection. A single C'4-labeled metabolite, accounting for nearly all of the urinary radioactivity, was isolated from rat urine and partially characterized.
3. Biliary excretion of the administered radioactivity was substantial (83% of the dose) and rapid (to, 10 hours) in rats. Thyroxine glucuronide was the principal biliary metabolite, along with small amounts of free thyroxine and a third unidentified C'4-labeled metabolite.
4. When a mixture of ring-labeled L-thyroxine-C14 and L-thyroxine-(3',5'-_131) was given to man, both C'4 and I13' were removed exponentially from plasma at essentially the same rate (tj, 6.8 days) . With the dog, the rate of removal for C14 was much faster than in man (ti, 15 hours), and the plasma decay for I131 was greatly prolonged and nonexponential.
The urinary excretion of 1131 exceeded that for C14 in rat, dog, and man, with the dog showing the greatest disproportion. In the rat, it was demonstrated that the C14-labeled urinary metabolite did not contain radioactive iodine.
